INBX Inhibrx: Earnings per share for the last 12 months

Inhibrx Biosciences Inc (INBX) - corporate logo

This daily price chart for Inhibrx Biosciences (INBX) EPS (TTM) captures the metric at 11.60. The business's competitiveness is bolstered by a solid cash reserve and patent protection for early oncology drugs. Inhibrx Biosciences develops multipurpose protein systems where specialized antibodies create a closed therapeutic cycle. Revenue is generated through the sale of unique protein treatments for orphan diseases via government funds and insurers.

Inhibrx Biosciences Inc (INBX) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/17/2026

INBX (Inhibrx): analytical breakdowns and indicator data

- price and consensus price forecast:
Fundamental company valuation:INBX Inhibrx Biosciences Inc
Flagship merchandise of Inhibrx Biosciences, Inc.

The investment attractiveness of Inhibrx Biosciences (INBX) is based on the commercialization potential of innovative protein drugs for oncology therapy. This indicator measures the dynamics of net income per share over twelve months, reflecting the monetization efficiency of R&D assets. By analyzing the current eps YoY ttm trajectory, an investor can promptly identify business micro-slowdowns against a backdrop of high borrowing costs. Stable growth of this metric confirms capital resilience and the success of drug development.

Direct competitors

Net earnings per one share for the last twelve months Incyte Corp|HCM: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months NUVB|DAWN (dayonebio.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months monopartx.com (MNPR)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics Inc HRTX|Nuvectis Pharma, Inc - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BeyondSpring Pharma BYSI|Net earnings per share for the last 12 months BCAB|Net earnings per one share for the last twelve months Lixte Biotechnology LIXT|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals Inc.)|CLRB (Cellectar Biosciences, Inc.) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (Can-Fite BioPharma Ltd.)|Aprea Therapeutics, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (kaziatherapeutics.com)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana Corp (NCNA)|Earnings per share for the last twelve months Chimerix|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Corporation (KRON)|Earnings per share for the last twelve months Kintara KTRA|ONCT (Oncternal Therapeutics, Inc.) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months